Literature DB >> 11120996

Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative.

S Bobin-Dubreux1, M E Reverdy, C Nervi, M Rougier, A Bolmström, F Vandenesch, J Etienne.   

Abstract

A Staphylococcus aureus strain with low-level heteroresistance to vancomycin (designated MER) but susceptible to methicillin was isolated from an outpatient with conjunctivitis who did not receive any glycopeptide antibiotics. Incubation of the parent strain, MER, with increasing concentrations of vancomycin led to rapid selection of a stable progeny homogeneously resistant to vancomycin. Electron micrographs of strain MER showed enhanced cell wall thickness and abnormal septations typically seen with methicillin-resistant S. aureus having intermediate susceptibility to vancomycin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120996      PMCID: PMC90291          DOI: 10.1128/AAC.45.1.349-352.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-08-22       Impact factor: 17.586

3.  Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

Authors:  R F Pfeltz; V K Singh; J L Schmidt; M A Batten; C S Baranyk; M J Nadakavukaren; R K Jayaswal; B J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

Authors:  M C Ploy; C Grélaud; C Martin; L de Lumley; F Denis
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

5.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

6.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

7.  Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

Authors:  H Hanaki; K Kuwahara-Arai; S Boyle-Vavra; R S Daum; H Labischinski; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-08       Impact factor: 5.790

8.  Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction.

Authors:  K Murakami; W Minamide; K Wada; E Nakamura; H Teraoka; S Watanabe
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis.

Authors:  N Mani; P Tobin; R K Jayaswal
Journal:  J Bacteriol       Date:  1993-03       Impact factor: 3.490

  9 in total
  21 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

Authors:  Isabelle Verdier; Marie-Elisabeth Reverdy; Jerome Etienne; Gérard Lina; Michèle Bes; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil.

Authors:  I C V Palazzo; M L C Araujo; A L C Darini
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.

Authors:  Hitoshi Komatsuzawa; Kouji Ohta; Sakuo Yamada; Kerstin Ehlert; Harald Labischinski; Junko Kajimura; Tamaki Fujiwara; Motoyuki Sugai
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Mélanie Roch; Perrine Clair; Adriana Renzoni; Marie-Elisabeth Reverdy; Olivier Dauwalder; Michèle Bes; Annie Martra; Anne-Marie Freydière; Frédéric Laurent; Philippe Reix; Oana Dumitrescu; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 6.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation.

Authors:  Paige M Fox; Michael W Climo; Gordon L Archer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

8.  An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus.

Authors:  Franziska Schaaff; Andrea Reipert; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

9.  Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.

Authors:  Andrea Reipert; Kerstin Ehlert; Thomas Kast; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 10.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.